Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides

Critical Care Medicine

Volumn 33, Issue 9, 2005, Pages 1983-1987

  Rello, Jordi ^a   Sole Violan, Jordi ^b   Sa Borges, Marcio ^c,d   Garnacho Montero, Jose ^e   Muñoz, Emma ^a   Sirgo, Gonzalo ^a,d   Olona, Montserrat ^a   Diaz, Emili ^a  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^c HOSPITAL SON LLÀTZER   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Methicillin resistant Staphylococcus aureus; Mortality; Oxacillin resistant Staphylococcus aureus; Therapy; Vancomycin; Ventilator associated pneumonia

Indexed keywords

CORTICOSTEROID; GLYCOPEPTIDE; LINEZOLID; OXACILLIN; TEICOPLANIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; STAPHYLOCOCCUS AUREUS; SURVIVAL; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 24944459102     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000178180.61305.1D     Document Type: Article

References (25)

1. CDC NNIS System. National nosocomial infections surveillance (NNIS) system report, data summary from January 1990-May 1999. Am J Infect Control 1999; 27:520-532
2. Vincent JL, Bihari DJ, Suter PM, et al: The prevalence of nosocomial infection in intensive care in Europe. JAMA 1995; 274:639-644
3. Kollef MH, Fraser VJ: Antibiotic resistance in the intensive care unit setting. Ann Intern Med 2001; 134:298-314
4. Chaix C, Durand-Zaleski I, Alberti C, et al: Control of endemic methicillin-resistant Staphylococcus aureus. JAMA 1999; 282:1745-1751
5. Rello J, Torres A, Ricart M, et al: Ventilator-associated pneumonia by Staphylococcus aureus. Am J Respir Crit Care Med 1994; 150:1545-1549
6. Wunderink RG, Rello J, Cammarata SK, et al: Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789-1797
7. Kollef MH, Rello J, Cammarata SK, et al: Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30:388-394
8. Harris AD, Karchmer TB, Carmeli Y, et al: Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: A systematic review. Clin Infect Dis 2001; 32:1055-1061
9. Blot SI, Vandewoude KH, Hoste EA, et al: Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002; 162:2229-2235
10. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 11th informational supplement. Wayne: NCCLS, 2001
11. Rello J, Ollendorf DA, Oster G, et al: Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002; 122:2115-2121
12. Rello J, Jubert P, Valles J, et al: Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa. Clin Infect Dis 1996; 23:973-978
13. Garnacho J, Sole-Violan J, Sa-Borges M, et al: Clinical impact of pneumonia cause by Acinetobacter baumannii in intubated patients. Crit Care Med 2003; 31:2478-2482
14. Nathwani D, Tillotson GS: Vancomycin for Staphylococcus aureus therapy of respiratory tract infections: The end of an era? Int J Antimicrob Ag 2003; 21:521-524
15. Pujol M, Pena C, Pallares R, et al: Risk factors for nosocomial bacteremia due to methicillin-resistant S. aureus. Eur J Clin Microbiol Infect Dis 1994; 13:96-102
16. Gonzalez C, Rubio M, Romero-Vivas J, et al: Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-sensitive organisms. Clin Infect Dis 1999; 29:1171-1177
17. Moise PA, Schentag JJ: Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Ag 2000; 16:S31-S34
18. Lamer C, de Beco V, Soler P, et al: Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37:281-286
19. Cruciani M, Gatti G, Lazzarini L, et al: Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 35:865-869
20. Wysocki M, Delatour F, Faurisson F, et al: Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: Prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45:2460-2467
21. Combes A, Luyt CE, Fagon JY, et al, for the PNEUMA Trial Group: Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator- associated pneumonia. Am J Respir Crit Care Med 2004; 170:786-792
22. Pea F, Brollo L, Viale P, et al: Teicoplanin therapeutic drug monitoring in critically ill patients: A retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother 2003; 51:971-975
23. Rello J, Ochagavia A, Sabanes E, et al: Evaluation of outcome of intravenous catheter-related infections in critically ill patients. Am J Respir Crit Care Med 2000; 162:1027-1030
24. Blot SI, Vanderwoude KH, Hoste EA, et al: Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002; 113:480-485
25. Kim SH, Park WB, Lee KD, et al: Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2004; 54:489-497